Sehtaj Kaur, Asit Kumar Mittal, Shaifali Jain, Laxman Kumar
{"title":"氮唑嘌呤毒性的早期征兆:厌氧原排出物。","authors":"Sehtaj Kaur, Asit Kumar Mittal, Shaifali Jain, Laxman Kumar","doi":"10.59556/japi.73.1073","DOIUrl":null,"url":null,"abstract":"<p><p>Azathioprine is a purine analog which is Food and Drug Administration (FDA) approved for organ transplant and severe rheumatoid arthritis (RA). Off-label use in dermatological diseases like immunobullous diseases, atopic dermatitis, autoimmune connective tissue disorders like systemic lupus erythematosus (SLE) and dermatomyositis, and other medical conditions like Crohn's disease, Churg-Strauss syndrome, and myasthenia gravis has long been in the picture.<sup>1-3</sup> The active metabolite of this prodrug is 6-thioguanine (6-TG), which gets incorporated into DNA/RNA structure, causing decreased purine metabolism resulting in its immunosuppressive effect. Thiopurine methyltransferase (TPMT) converts 6-mercaptopurine (6-MP) to an inactive metabolite. TPMT deficiency will cause increased conversion of 6-MP to active metabolite 6-TG, which increases the risk of myelosuppression, one of the life-threatening side effects of the drug.<sup>1,2</sup>.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 8","pages":"104-105"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anagen Effluvium as an Early Sign of Azathioprine Toxicity.\",\"authors\":\"Sehtaj Kaur, Asit Kumar Mittal, Shaifali Jain, Laxman Kumar\",\"doi\":\"10.59556/japi.73.1073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Azathioprine is a purine analog which is Food and Drug Administration (FDA) approved for organ transplant and severe rheumatoid arthritis (RA). Off-label use in dermatological diseases like immunobullous diseases, atopic dermatitis, autoimmune connective tissue disorders like systemic lupus erythematosus (SLE) and dermatomyositis, and other medical conditions like Crohn's disease, Churg-Strauss syndrome, and myasthenia gravis has long been in the picture.<sup>1-3</sup> The active metabolite of this prodrug is 6-thioguanine (6-TG), which gets incorporated into DNA/RNA structure, causing decreased purine metabolism resulting in its immunosuppressive effect. Thiopurine methyltransferase (TPMT) converts 6-mercaptopurine (6-MP) to an inactive metabolite. TPMT deficiency will cause increased conversion of 6-MP to active metabolite 6-TG, which increases the risk of myelosuppression, one of the life-threatening side effects of the drug.<sup>1,2</sup>.</p>\",\"PeriodicalId\":22693,\"journal\":{\"name\":\"The Journal of the Association of Physicians of India\",\"volume\":\"73 8\",\"pages\":\"104-105\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of the Association of Physicians of India\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.59556/japi.73.1073\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Association of Physicians of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59556/japi.73.1073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Anagen Effluvium as an Early Sign of Azathioprine Toxicity.
Azathioprine is a purine analog which is Food and Drug Administration (FDA) approved for organ transplant and severe rheumatoid arthritis (RA). Off-label use in dermatological diseases like immunobullous diseases, atopic dermatitis, autoimmune connective tissue disorders like systemic lupus erythematosus (SLE) and dermatomyositis, and other medical conditions like Crohn's disease, Churg-Strauss syndrome, and myasthenia gravis has long been in the picture.1-3 The active metabolite of this prodrug is 6-thioguanine (6-TG), which gets incorporated into DNA/RNA structure, causing decreased purine metabolism resulting in its immunosuppressive effect. Thiopurine methyltransferase (TPMT) converts 6-mercaptopurine (6-MP) to an inactive metabolite. TPMT deficiency will cause increased conversion of 6-MP to active metabolite 6-TG, which increases the risk of myelosuppression, one of the life-threatening side effects of the drug.1,2.